FcRN receptor antagonists in the management of myasthenia gravis.

Front Neurol · 2023 · PMC10439012 · PMID 37602255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the rozanolixizumab group showed an overall improvement in outcome measures compared to the placebo group from baseline to day 29, the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.